Join the 'Xolair' group to help and get support from people like you. How it works
Xolair Blog
| Tweet |
Allergy Drug May Speed Up Kids' Ability to Tolerate Milk
Posted 22 Mar 2011 by Drugs.com
MONDAY, March 21 – Kids who are allergic to milk may be able to quickly develop tolerance by coupling the allergy medication Xolair with a gradual increase in their exposure to milk, known as sensitization, a new study suggests. An estimated 3 million children in the United States are allergic to some kind of food. Milk allergy is the most common food allergy among children, affecting about 2.5 percent of those younger than 3. Treatment based on sensitization alone – exposing children to small but progressively greater amounts of the food substance to which they're allergic – is often successful. But it's usually a slow process that runs the risk of provoking allergic reactions. Seeking a faster and safer method, the research team tested a dual approach – sensitization along with Xolair (omalizumab), a drug that blocks the action of IgE, a natural substance in the body that causes ... Read more
Xolair Reduces Seasonal Asthma Attacks for Inner City Kids: Study
Posted 16 Mar 2011 by Drugs.com
WEDNESDAY, March 16 – The injectable medication Xolair reduced asthma symptoms in inner city children with the respiratory condition, and almost eliminated seasonal peaks in asthma attacks, new research shows. When added to standard asthma treatments, Xolair (omalizumab) decreased the amount of inhaled steroid needed to maintain asthma control, according to the study, which is published in the March 17 issue of the New England Journal of Medicine. "Omalizumab improves asthma control on top of guidelines-based treatment," said study co-author Dr. William Busse, a professor of medicine at the University of Wisconsin School of Medicine in Madison. "There was less need for other medications, a reduction of symptoms and reduction of the seasonal exacerbations of asthma. Omalizumab almost totally eliminated these attacks." But, he added, it's too soon to make treatment recommendations based ... Read more
Related support groups: Asthma, Xolair, Omalizumab
FDA Investigating Safety of Asthma Drug Xolair
Posted 16 Jul 2009 by Drugs.com
THURSDAY, July 16 – The U.S. Food and Drug Administration has begun a safety review of the asthma drug Xolair (omalizumab) after reports of an increased risk of heart attack, abnormal heart rhythm, heart failure, and stroke, the agency said Thursday. Early results from the Evaluating the Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS) trial spurred the investigation, the FDA said. The results indicate that Xolair boosts the risk of heart problems among users of the drug compared with nonusers. The data from the trial was supplied to the FDA by Genentech, the maker of Xolair. The trial includes some 5,000 patients taking the drug and an additional 2,500 patients who are not using Xolair, according to the FDA. Xolair, which is given by injection, is used for those people whose asthma is not controlled by inhaled corticosteroids. Currently, ... Read more
Related support groups: Xolair
FDA Medwatch Alert: Xolair (omalizumab)
Posted 21 Feb 2007 by Drugs.com
Indications and Usage: for treatment of adults and adolescents (12 years of age and above) with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. Xolair has been shown to decrease the incidence of asthma exacerbations in these patients. Safety and efficacy have not been established in other allergic conditions. [Posted 02/21/2007] FDA notified asthmatic patients and healthcare professionals of new reports of serious and life-threatening allergic reactions (anaphylaxis) in patients after treatment with Xolair (omalizumab). Usually these reactions occur within two hours of receiving a Xolair subcutaneous injection. However, these new reports include patients who had delayed anaphylaxis—with onset two to 24 hours or even longer—after ... Read more
Related support groups: Xolair